CKCarsten Kroll

Carsten Kroll

*This is an algorithmically generated author record based on publicly available information.

Carsten Kroll has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Translational Application of the Five-Star Matrix for the Structure-Guided Optimization of a Bicyclopiperazine DEL Hit into Bcpz 1.5: A Potent Monoacylglycerol Lipase Inhibitor with Functional Inhibition in Human Brain Homogenate and Efficacy in Neuroinflammatory Models

    by Benjamin Brennecke, Louise Plais, Benoit Hornsperger, Martin Binder, Christian Bartelmus, Markus BürKler, Fionn O’HAra, Carsten Kroll, Satoshi Tsuchiya, Buelent Kocer, et al.

    Monoacylglycerol lipase (MAGL) is a promising therapeutic target for neuroinflammatory conditions. We have previously reported on MAGLi 432, a reversible MAGL inhibitor with activity in mouse models of neuroinflammation. In this full account, we report on the structure-guided optimization of a bicyclopiperazine (Bcpz) DEL hit into potent, selective and brain-penetrant reversible MAGL inhibitor 1.5 (MAGLi 432), guided by the “Five-Star Matrix” translational framework. Compound 1.5 combines excellent MAGL potency (IC50 = 3.2 nM) and selectivity over other serine hydrolases with favorable pharmacokinetic properties, including a 5.7 h half-life after oral administration in male Wistar rats, and CNS drug-like potential. Furthermore, as previously reported, the compound demonstrated robust brain penetration and efficacy in preclinical mouse models of neuroinflammation correlating with inhibition of MAGL activity in mouse and human brain homogenate. This work highlights the power of combining DEL screening and SBDD with the Five-Star Matrix to deliver drug-like candidates for neuroinflammatory disorders.

  • Dynlog P A Novel High-Throughput LC−MS Assay Quantifying Dynamic Lipophilicity and Chameleonicity of bRo5 Macrocyclic Peptides

    by Christian Weinmann, Franz Waibl, Silvan KäsEr, Fabio Casagrande, Jitao David Zhang, Fabian Dey, BjörN Wagner, Britta Schulze, Carsten Kroll, Janneke Keemink

    The landscape of drug discovery has expanded beyond the traditional chemical space into the domain of large, flexible molecules, including beyond rule-of-five (bRo5) macrocyclic peptides (MCPs). Molecular chameleonicity, the capacity to dynamically adapt the conformation to the environment, balancing aqueous solubility and membrane permeability, has the potential to improve the oral bioavailability of these compounds. However, we lack experimental methods that quantify chameleonicity in a high-throughput manner. To address this need, we introduce DynlogP, a novel high-throughput, fully automated assay based on reverse-phase LC−MS that can quantify chameleonicity with minimal compound input. DynlogP measures calibrated lipophilicity under conditions promoting either solvent hydrogen bonding (log P70) or intramolecular hydrogen bonding (log P95), providing a quantitative measure of chameleonicity (Δlog P95−70) that is validated with NMR and molecular dynamics simulations. We profiled hundreds of molecules with DynlogP and demonstrate that chameleonicity is a common feature of MCPs. Machine learning models trained with DynlogP data allow for the prospective prediction of chameleonicity. Adoption and further refinement of DynlogP have the potential to empower compound prioritization and the design of orally bioavailable MCP-based therapeutics.

  • Structure-Guided Discovery of cis-Hexahydro-pyrido-oxazinones as Reversible, Drug-like Monoacylglycerol Lipase Inhibitors

    by Bernd Kuhn, Martin Ritter, Benoit Hornsperger, Charles Bell, Buelent Kocer, Didier Rombach, Marius D. R. Lutz, Luca Gobbi, Martin Kuratli, Christian Bartelmus, et al.

    Monoacylglycerol lipase (MAGL) is a key enzyme involved in the metabolism of the endogenous signaling ligand 2-arachidonoylglycerol, a neuroprotective endocannabinoid intimately linked to central nervous system (CNS) disorders associated with neuroinflammation. In the quest for novel MAGL inhibitors, a focused screening approach on a Roche library subset provided a reversible benzoxazinone hit exhibiting high ligand efficiency. The subsequent design of the three-dimensional cis-hexahydro-pyrido-oxazinone (cis-HHPO) moiety as benzoxazinone replacement enabled the combination of high MAGL potency with favorable ADME properties. Through enzymatic resolution an efficient synthetic route of the privileged cis-(4R,8S) HHPO headgroup was established, providing access to the highly potent and selective MAGL inhibitor 7o. Candidate molecule 7o matches the target compound profile of CNS drugs as it achieves high CSF exposures after systemic administration in rodents. It engages with the target in the brain and modulates neuroinflammatory processes, thus holding great promise for the treatment of CNS disorders.